Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
出版年份 2022 全文链接
标题
Molecular landscape of
TP53
mutations in breast cancer and their utility for predicting the response to
HER
‐targeted therapy in
HER2
amplification‐positive and
HER2
mutation‐positive amplification‐negative patients
作者
关键词
-
出版物
Cancer Medicine
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2022-04-08
DOI
10.1002/cam4.4652
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
- (2020) Matteo Canale et al. Journal of Clinical Medicine
- Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
- (2020) Olga Fedorova et al. Cell Death Discovery
- Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
- (2019) Zongbi Yi et al. BMC CANCER
- Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
- (2019) Qiao Li et al. CLINICAL CANCER RESEARCH
- Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer
- (2019) Collins et al. Cancers
- Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer
- (2019) Fei Ma et al. INTERNATIONAL JOURNAL OF CANCER
- Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
- (2019) Lawrence A. Donehower et al. Cell Reports
- Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
- (2019) Helei Hou et al. Cancer Management and Research
- Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
- (2019) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib
- (2019) Jun Zhao et al. LUNG CANCER
- WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer
- (2019) Andrea Sand et al. CANCER LETTERS
- Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
- (2018) Michael J. Duffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells
- (2018) Alisha Yallowitz et al. Cell Death & Disease
- The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
- (2018) Pedram Razavi et al. CANCER CELL
- Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy
- (2018) Siqing Fu et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- Maftools: efficient and comprehensive analysis of somatic variants in cancer
- (2018) Anand Mayakonda et al. GENOME RESEARCH
- Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
- (2018) Youjin Kim et al. Journal of Thoracic Oncology
- Mutant p53 as a target for cancer treatment
- (2017) Michael J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
- (2017) Fei Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)
- (2017) Catherine Labbé et al. LUNG CANCER
- Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
- (2017) Zongbi Yi et al. Scientific Reports
- Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
- (2016) Matteo Canale et al. CLINICAL CANCER RESEARCH
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress
- (2014) D Li et al. Cell Death & Disease
- p53 in breast cancer subtypes and new insights into response to chemotherapy
- (2013) Philippe Bertheau et al. BREAST
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now